No-reflow phenomenon

Clinical trials for No-reflow phenomenon explained in plain language.

Never miss a new study

Get alerted when new No-reflow phenomenon trials appear

Sign up with your email to follow new studies for No-reflow phenomenon, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 3 Not yet recruiting 2 Not yet finished but already full! 1 Completed 2

Diabetes drug could shield heart muscle during angioplasty

Disease control Ongoing

This phase 2 trial tests whether empagliflozin (Jardiance), a diabetes drug, can reduce the 'no-reflow' phenomenon—when blood flow fails to fully restore after angioplasty—in 162 heart attack patients. Participants receive a loading dose before the procedure and daily doses for 3…

Matched conditions: NO-REFLOW PHENOMENON

Phase 2 • Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez • Aim: Disease control

Last updated Jun 27, 2026 12:07 UTC

No-reflow phenomenon

Get alerted when new No-reflow phenomenon trials appear

Diabetes drug could shield heart muscle during angioplasty